Araloside C

Araloside C exhibits protective effects against myocardial ischaemia/reperfusion injury.

Product information

CAS Number: 55446-15-6

Molecular Weight: 1089.22

Formula: C53H84O23

Chemical Name: (2S, 3S, 4R, 5R, 6R)-6-{[(3S, 4aR, 6aR, 6bS, 8aS, 12aS, 14aR, 14bR)-4, 4, 6a, 6b, 11, 11, 14b-heptamethyl-8a-({[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}carbonyl)-1, 2, 3, 4, 4a, 5, 6, 6a, 6b, 7, 8, 8a, 9, 10, 11, 12, 12a, 14, 14a, 14b-icosahydropicen-3-yl]oxy}-3-{[(2S, 3R, 4S, 5R)-3, 5-dihydroxy-4-{[(2S, 3R, 4S, 5S, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl]oxy}-4, 5-dihydroxyoxane-2-carboxylic acid

Smiles: C[C@@]12CC[C@]3(CCC(C)(C)C[C@H]3C1=CC[C@H]1[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@H](O[C@@H]1O[C@@H]([C@@H](O[C@@H]3OC[C@@H](O)[C@H](O[C@@H]4O[C@H](CO)[C@@H](O)[C@H](O)[C@H]4O)[C@H]3O)[C@H](O)[C@H]1O)C(O)=O)C2(C)C)C(=O)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O

InChiKey: DBUJWVDNMXCCKD-MVIACUKKSA-N

InChi: InChI=1S/C53H84O23/c1-48(2)14-16-53(47(68)76-45-36(63)33(60)31(58)26(20-55)71-45)17-15-51(6)22(23(53)18-48)8-9-28-50(5)12-11-29(49(3,4)27(50)10-13-52(28,51)7)72-46-37(64)34(61)40(41(75-46)42(66)67)74-43-38(65)39(24(56)21-69-43)73-44-35(62)32(59)30(57)25(19-54)70-44/h8,23-41,43-46,54-65H,9-21H2,1-7H3,(H,66,67)/t23-,24+,25+,26+,27-,28+,29-,30+,31+,32-,33-,34+,35+,36+,37+,38+,39-,40-,41-,43-,44-,45-,46+,50-,51+,52+,53-/m0/s1

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Araloside C also up-regulates the expression levels of Hsp90 and improved cell viability in hypoxia/reoxygenation-treated H9c2 cardiomyocytes, whereas the addition of 17-AAG, a pharmacologic inhibitor of Hsp90, attenuates Araloside C-induced cardioprotective effect. Araloside C (0.5-2.5 μM) concentration-dependently improves the functional recovery of the I/R hearts, including increase in the recovery of LVDP, dP/dtmax and heart rate throughout the reperfusion period, although the baseline mechanical parameters with Araloside C were not significantly different compared with those of the control condition. Araloside C could improve post-ischaemic cell shortening and Ca2+ transients from 2 to 8 μM.

Products are for research use only. Not for human use.